Viking Therapeutics (VKTX) is rated as one of the best healthcare stocks with high upside potential, receiving Buy ratings from analysts with price targets of $100 and $102. The company’s competitive efficacy and safety data in GLP-1 programs position it as a strong candidate for potential mergers and acquisitions. Despite operating in a competitive landscape, Viking Therapeutics shows promise for growth and strategic opportunities. The company focuses on developing therapies for metabolic and endocrine disorders. While VKTX is a potential investment, other AI stocks may offer greater upside potential with less downside risk.

Read more at Yahoo Finance: Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer